Mitobridge
Mitobridge is a privately held biotechnology company founded in 2011 in Cambridge, Massachusetts, developing small molecule therapeutics that improve mitochondrial functions. It targets mitochondrial disease through medicinal chemistry-driven drug discovery, backed by MPM Capital, Longwood Fund, and Astellas Pharma.
- Company typePrivate
- Founded2011
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mitobridge does
Mitobridge is a privately held biotechnology company founded in 2011 in Cambridge, Massachusetts. According to its firmographic profile, the company discovers and develops small molecule therapeutics aimed at improving mitochondrial functions, positioning it within the mitochondrial disease and bioenergetics therapeutic space. It operates with a lean organization of 11–50 employees and maintains a web presence at mitobridge.com.
The company has raised capital from a syndicate of biotech-focused investors. Its initial founding event in 2011 was backed by MPM Capital, and a subsequent disclosed equity round on October 4, 2013, totaled approximately $5.22 million with participation from Longwood Fund and a strategic pharmaceutical investor, Astellas Pharma. Capital has been directed toward building a small molecule drug discovery platform with explicit medicinal chemistry capability, evidenced by the hiring of Takeru Furuya as Associate Director of Medicinal Chemistry and founder-led oversight from Kazumi Shiosaki, who serves as President & CEO.
As a development-stage biotech with no disclosed commercial products, partnerships, or licensing revenue, Mitobridge's progress depends on continued financing, scientific milestones, or strategic transactions. The early-stage strategic investment by Astellas Pharma is notable as a signal of pharma-level validation of the mitochondrial therapeutic thesis and as a potential channel for future partnership, licensing, or acquisition activity. The data set does not disclose post-2013 financing, pipeline progression, or headcount trends, limiting visibility into the company's current operating trajectory.
Mitobridge firmographics
Firmographics- Name
- Mitobridge
- Legal name
- Slabmedia, LLC
- Website
- https://mitobridge.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mitobridge is a privately held biotechnology company founded in 2011 in Cambridge, Massachusetts, developing small molecule therapeutics that improve mitochondrial functions. It targets mitochondrial disease through medicinal chemistry-driven drug discovery, backed by MPM Capital, Longwood Fund, and Astellas Pharma.
- Ownership category
- akta.pro rank
Mitobridge industry classification
Industry- Product category
- Mitochondrial Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)
- akta.pro secondary industry
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)
Keywords
Where Mitobridge is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mitobridge business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Web Design and Development Services: Custom website design and development services using hand-coded solutions without templates. Includes ongoing support, updates, and custom functionality creation. Revenue generated through project-based engagements and service contracts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Custom Service Levels & Pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Mitobridge product offering
Product offeringCore offering
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. The company focuses on mitochondrial biology to identify orally bioavailable drug candidates targeting diseases linked to mitochondrial dysfunction, including rare genetic mitochondrial disorders and broader metabolic indications. It operates as a preclinical-stage biopharmaceutical research organization based in Cambridge, Massachusetts.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Tremendous positive client feedback for law firm website - serves industry perfectly
Companies that use Mitobridge
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles1 record
Mitobridge technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mitobridge partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Mitobridge competitors and assessment
Company assessmentOthers
- MPM Capital: Healthcare-dedicated venture capital firm that seeded and led Mitobridge's Series A; comparable as an investor in the mitochondrial/rare-disease biotech ecosystem rather than a product peer.
- Longwood Fund: Boston-area biotech venture firm and Mitobridge Series A co-investor; comparable as a fellow investor in early-stage Cambridge biotechs rather than as a product competitor.
Direct peers
- Stealth BioTherapeutics: Clinical-stage biotech developing small molecule therapeutics targeting mitochondrial dysfunction across rare diseases and ophthalmology; the most directly comparable mitochondrial small-molecule peer to Mitobridge.
- Pretzel Therapeutics: Mitochondrial disease biotech developing both small molecule and gene therapy approaches for disorders of mitochondrial function; comparable indication focus though broader modality.
- Minovia Therapeutics: Clinical-stage company developing mitochondrial cell therapies and small molecule approaches for mitochondrial diseases; comparable in mitochondrial mechanism and rare disease focus.
- CohBar: Clinical-stage biotech developing mitochondria-derived peptides (MDBPs) for metabolic and age-related diseases; comparable in addressing mitochondrial biology for systemic disease.
- NRG Therapeutics: Discovery/preclinical-stage company developing small molecule inhibitors of mitochondrial permeability transition pore for neurodegenerative diseases; comparable mitochondrial-mechanism focus.
- Khondrion: Clinical-stage mitochondrial therapeutics company developing small molecules for inherited mitochondrial diseases; closely comparable in modality and disease focus.
- Abliva: Swedish clinical-stage biotech developing therapies for primary mitochondrial disease, including both small molecule and NAD+ precursor approaches; comparable therapeutic area and stage.
Broad incumbents
- Astellas Pharma: Global Japanese pharmaceutical company and existing Mitobridge investor; broader portfolio across multiple therapeutic areas, with strategic interest in mitochondrial and rare disease programs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Mitobridge social profiles
Digital presenceMitobridge financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mitobridge leadership team
Management profileNumber of profiles
Profiles2 records
Mitobridge funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mitobridge M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mitobridge
What does Mitobridge do?
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. The company focuses on mitochondrial biology to identify orally bioavailable drug candidates targeting diseases linked to mitochondrial dysfunction, including rare genetic mitochondrial disorders and broader metabolic indications. It operates as a preclinical-stage biopharmaceutical research organization based in Cambridge, Massachusetts.
Is Mitobridge a public or private company?
Mitobridge is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mitobridge founded?
Mitobridge was founded in 2011. It employs 11 to 50 people.
Where is Mitobridge based?
Mitobridge is headquartered in Cambridge, United States, in the North America region.
How does Mitobridge make money?
One revenue line is on record: web Design and Development Services.
Who are Mitobridge's main competitors?
Others on record are MPM Capital and Longwood Fund. Direct peers are Stealth BioTherapeutics, Pretzel Therapeutics, Minovia Therapeutics, CohBar, NRG Therapeutics, Khondrion and Abliva. Astellas Pharma is listed as a broad incumbent.
Does Mitobridge have an API?
No public API is recorded for Mitobridge.
What industry is Mitobridge in?
Mitobridge's product category is Mitochondrial Therapeutics. Its primary akta.pro industry code is HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives, with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 2835.